Semaxanib

Generic Name: Semaxanib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₅H_₁₄N_₂O

CAS Number: 194413-58-6

Unique Ingredient Identifier: 71IA9S35AJ

Indication: Investigated for use/treatment in colorectal cancer and lung cancer.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

SU5416 in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Previous Treatment

Phase 2

Terminated

Conditions: Recurrent Renal Cell Cancer
Stage IV Renal Cell Cancer

Interventions: Drug: semaxanib

First Posted Date: 2004-01-01

Last Posted Date: 2013-01-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 50

Registration Number: NCT00009919

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

SU5416 in Treating Children With Recurrent or Progressive Brain Tumors

Phase 1

Terminated

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2003-12-24

Last Posted Date: 2009-10-14

Lead Sponsor: Pediatric Brain Tumor Consortium

Target Recruit Count: 33

Registration Number: NCT00006247

Locations: 🇺🇸
Duke Comprehensive Cancer Center, Durham, North Carolina, United States
🇺🇸
Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸
Saint Jude Children's Research Hospital, Memphis, Tennessee, United States

and more 6 locations

SU5416 and Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer

Phase 2

Completed

Conditions: Kidney Cancer

First Posted Date: 2003-12-24

Last Posted Date: 2011-10-20

Lead Sponsor: City of Hope Medical Center

Registration Number: NCT00006384

Locations: 🇺🇸
Cancer Center and Beckman Research Institute, City of Hope, Duarte, California, United States
🇺🇸
University of California Davis Cancer Center, Sacramento, California, United States
🇺🇸
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States

SU5416 in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2003-12-17

Last Posted Date: 2010-06-11

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 19

Registration Number: NCT00005642

Locations: 🇺🇸
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Chemotherapy, SU5416, Radiation Therapy, and Surgery in Treating Patients With Soft Tissue Sarcoma

Phase 1

Completed

Conditions: Sarcoma

First Posted Date: 2003-10-21

Last Posted Date: 2013-06-24

Lead Sponsor: Radiation Therapy Oncology Group

Registration Number: NCT00023738

Locations: 🇺🇸
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
🇺🇸
Harbor Hospital Center, Baltimore, Maryland, United States
🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

and more 223 locations

SU5416 in Treating Patients With Persistent or Recurrent Cervical Cancer

Phase 2

Completed

Conditions: Cervical Cancer

First Posted Date: 2003-10-21

Last Posted Date: 2013-06-24

Lead Sponsor: Gynecologic Oncology Group

Registration Number: NCT00026260

Radiation Therapy With or Without SU5416 in Treating Patients With Soft Tissue Sarcoma

Phase 1

Completed

Conditions: Sarcoma

First Posted Date: 2003-10-15

Last Posted Date: 2013-06-24

Lead Sponsor: Radiation Therapy Oncology Group

Registration Number: NCT00023725

Locations: 🇺🇸
Veterans Affairs Medical Center - Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States

and more 223 locations

SU5416 and Paclitaxel in Treating Patients With Advanced Cancer

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2003-10-08

Last Posted Date: 2010-01-13

Lead Sponsor: City of Hope Medical Center

Registration Number: NCT00006257

Locations: 🇺🇸
Cancer Center and Beckman Research Institute, City of Hope, Duarte, California, United States
🇺🇸
University of California Davis Cancer Center, Sacramento, California, United States
🇺🇸
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States

SU5416 Compared to Dexamethasone in Treating Patients With Progressive Prostate Cancer That Has Not Responded to Hormone Therapy

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: dexamethasone
Drug: semaxanib

First Posted Date: 2003-08-29

Last Posted Date: 2013-09-05

Lead Sponsor: University of Chicago

Target Recruit Count: 36

Registration Number: NCT00006002

Locations: 🇺🇸
Cancer Center and Beckman Research Institute, City of Hope, Duarte, California, United States
🇺🇸
Ingalls Memorial Hospital, Harvey, Illinois, United States
🇺🇸
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States

and more 15 locations

SU5416 in Treating Patients With Refractory or Relapsed Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

First Posted Date: 2003-06-25

Last Posted Date: 2013-07-11

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 21

Registration Number: NCT00006013

Locations: 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

and more 1 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy